Used primarily in the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with Philadelphia chromosome positivity. It functions as a tyrosine kinase inhibitor, targeting the BCR-ABL fusion protein that drives uncontrolled cell proliferation in these cancers. Also shows activity against other kinases such as SRC family kinases, making it effective in cases resistant to other therapies like imatinib. Administered orally, it enables long-term outpatient management of chronic leukemia. Ongoing research explores its potential in solid tumors and immune-related disorders due to its broad kinase inhibition profile.